Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

MURANO trial: Venetoclax-rituximab shows sustained benefit in relapsed...

Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia

$MURANO trial: Venetoclax-rituximab shows sustained benefit in relapsed/refractory chronic lymphocytic leukaemia ( Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )$

Glasdegib in combination with azacitidine in patients with untreated higher...

Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA

Glasdegib in combination with azacitidine in patients with untreated higher-risk myelodysplastic syndromes and AML ( Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA )

Addressing the treatment gap for patients with relapsed/refractory primary...

Prof Evangelos Terpos and Prof Efstathios Kastritis

$Addressing the treatment gap for patients with relapsed/refractory primary systemic AL amyloidosis: TOURMALINE-AL1 trial results ( Prof Evangelos Terpos and Prof Efstathios Kastritis )$

Carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

Challenges and importance of long-term treatment for newly diagnosed multiple...

Prof Sagar Lonial, Prof Meral Beksaç, Dr Robert Rifkin

Challenges and importance of long-term treatment for newly diagnosed multiple myeloma patients; community-based trial data ( Prof Sagar Lonial, Prof Meral Beksaç, Dr Robert Rifkin )

Novel multi-antigen targeted CAR-NK cell for the treatment of B cell...

Dr Bahram Valamehr - Fate Therapeutics Inc., San Diego, USA

Novel multi-antigen targeted CAR-NK cell for the treatment of B cell malignancies ( Dr Bahram Valamehr - Fate Therapeutics Inc., San Diego, USA )

Multiple myeloma: Anti-BCMA BiTE AMG 701 shows preclinical promise

Dr Yu-Tzu Tai - Dana-Farber Cancer Institute, Boston, USA

Multiple myeloma: Anti-BCMA BiTE AMG 701 shows preclinical promise ( Dr Yu-Tzu Tai - Dana-Farber Cancer Institute, Boston, USA )

Evaluating emerging mutations in patients with acute myeloid leukaemia who...

Dr Catherine Smith - University of California San Francisco, San Francisco, USA

Evaluating emerging mutations in patients with acute myeloid leukaemia who relapsed while receiving gilteritinib therapy in the ADMIRAL trial ( Dr Catherine Smith - University of California San Francisco, San Francisco, USA )

Maintenance decitabine after intensive therapy for AML in older FLT3-ITD...

Dr James Foran - Mayo Clinic Florida, Jacksonville, USA

Maintenance decitabine after intensive therapy for AML in older FLT3-ITD-negative patients ( Dr James Foran - Mayo Clinic Florida, Jacksonville, USA )

Bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma

Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China

Bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma ( Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China )

Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin...

Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA

Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients ( Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA )

CAR T-cell therapy in hard-to-treat multiple myeloma produces sustained...

Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China

CAR T-cell therapy in hard-to-treat multiple myeloma produces sustained remissions ( Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China )

More from ecancer